Real-World Molecular Testing Rates and Patterns in Patients With Primary Advanced or Recurrent Endometrial Cancer in the United States
Yilin Chen, Solomon J Lubinga, Troy Williams, Josh J, Carlson, Scott D. Ramsey
In a study published in JCO Precision Oncology, Curta investigators examined real-world molecular testing patterns in patients with primary advanced or recurrent endometrial cancer (pA/rEC) in the U.S.
📈 Key Findings
- Biomarker testing rates rose from 53% in 2013 to 89% in 2021, with significant increases in tests for MMR/MSI, ER/PR, and HER2.
- Patients treated at academic centers, with commercial insurance, or with primary advanced EC were more likely to receive testing.
- Despite progress, disparities persist—patients in community settings or with public insurance remain less likely to be tested.
💡 Why it matters: Molecular testing is essential for precision medicine. It enables access to targeted therapies that improve outcomes in endometrial cancer, particularly for biomarker-defined subgroups such as dMMR/MSI-H. Yet, not all patients have equitable access.
🏥 With most U.S. cancer patients receiving care in community settings, closing this testing gap is vital to realizing the promise of personalized oncology.
📚 This work, supported by GSK and powered by Flatiron Health’s real-world data, aims to inform policies and clinical practices that ensure every patient has access to timely, actionable biomarker testing.